학술논문
Editorial: Post COVID-19: the nucleoside-modified messenger RNA (modRNA) platform.
Document Type
Editorial & Opinion
Author
Roncati L; Department of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplantation, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.; Department of Laboratory Medicine and Anatomical Pathology, Institute of Pathology, University Hospital of Modena - Polyclinic, Modena, Italy.; Huo QT; Department of Chemistry, University of Central Florida, Orlando, FL, United States.; NanoScience Technology Center, University of Central Florida, Orlando, FL, United States.
Source
Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2296-858X
Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.